Since 2018, the Barretos Cancer Hospital, Barretos, SP, Brazil, has carried out molecular tests to subclassify a brain tumor called medulloblastoma that occurs most often in children, but can also occur in adults. This classification is important to direct more appropriate treatments. The method used to classify pediatric brain tumors involves the use of a state-of-the-art digital technology called NanoString that can detect and quantify hundreds of "RNA" molecules simultaneously and identify exactly which subtype of medulloblastoma.